Advanced search
Publication Cover
Disability and Rehabilitation Volume 38, 2016 - Issue 19
Submit an article Journal homepage
465
Views
5
CrossRef citations to date
0
Altmetric
Research Paper

Frequency and characteristics of goal attainment following BoNT-A injection for management of spasticity

Denita MullinsOccupational Therapy Department, Caulfield Hospital, Alfred Health, Caulfield, Australia; Correspondence[email protected]
,
Adele WinterPhysiotherapy Department, Caulfield Hospital, Alfred Health, Caulfield, Australia;
,
Natalie FiniPhysiotherapy Department, Caulfield Hospital, Alfred Health, Caulfield, Australia; ;Acquired Brain Injury Centre, Caulfield Hospital, Alfred Health, Caulfield, Australia;
,
Caroline DixonOccupational Therapy Department, Caulfield Hospital, Alfred Health, Caulfield, Australia;
,
Sara AldousEpworth HealthCare, Richmond, Australia;
,
Mithu PalitAcquired Brain Injury Centre, Caulfield Hospital, Alfred Health, Caulfield, Australia;
&
Anne E. HollandPhysiotherapy Department, Caulfield Hospital, Alfred Health, Caulfield, Australia; ;La Trobe University, Bundoora, Australia
 show all
Pages 1927-1933 | Received 19 Oct 2012, Accepted 10 Oct 2015, Published online: 30 Dec 2015

References

  • Sheean G, Lannin NA, Turner-Stokes L, et al. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17:74–93.
  • Sommerfeld D, Eek E, Svensson A, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35:134–139.
  • Watkins C, Leathley M, Gregson J, et al. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16:515–522.
  • Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30:1303–1313.
  • Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005;31:535–551.
  • Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115:607–616.
  • Wissel J, Ward A, Ertzgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41:13–25.
  • Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–990.
  • Elia AE, Filippini G, Calandrella D, et al. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord. 2009;24:801–812.
  • Sheehan G. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol. 2001;14:771–776.
  • Brashear A, McAfee AL, Kuhn ER, et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705–709.
  • Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil. 2009;23:362–370.
  • Turner-Stokes L, Baguley I, De Graaff S, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomised clinical trial. J Rehabil Med. 2010;42:81–89.
  • Ottenbacher K, Cusick A. Discriminative versus evaluative assessment: some observations on goal attainment scaling. Am J Occup Ther. 1993;47:349–354.
  • Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4:443–453.
  • Kiresuk TJ, Chaote RO. Applications of goal attainment scaling. In: Kiresuk TJ, Smith A, Cardillo JE, editors. Goal attainment scaling: applications, theory and measurement. Hillsdale, NJ: Lawrence Erlbaum; 1994, p. 61–104.
  • Morris S. Ashworth and Tardieu Scales: their clinical relevance for measuring spasticity in adult and paediatric neurological populations. Phys Ther Rev. 2002;7:53–62.
  • Hill K, Denisenko S, Miller K, et al. Mobility and gait. In: Clinical outcome measurement in adult neurological physiotherapy. 3rd ed. Melbourne: Australian Physiotherapy Association; 2005. p. 90–96.
  • Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int. 2006;11:24–34.
  • Chan J, Winter A, Palit M, et al. Are gait and mobility measures responsive to change following botulinum toxin injections in adults with lower limb spasticity? Disabil Rehabil. 2012;35:959–967. Early Online: 1–9.
  • National Stroke Foundation. Clinical guidelines for stroke management. Melbourne, Australia; 2010. p. 99.
  • Takekawa T, Kakuda W, Taguchi K, et al. Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke. Int J Rehabil Res. 2012;35:146–152.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.